AFFECTED PUBLIC: PARENTS AND THEIR TEENAGE CHILDREN

Type of respondents	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Parents	3,200	2	0.5	3,200
Adolescents	3,200	2	0.5	3,200

The annualized cost to respondents is estimated at $64000 (based on $10 per hour). There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT:

To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Bruce Simons-Morton, Chief, Prevention Research Branch, Division of Epidemiology, Statistics, and Prevention Research, National Institute of Child Health and Human Development, Building 6100, 7B05, 9000 Rockville Pike, Bethesda, Maryland, 20892–7510, or call non-toll free number (301) 496–5674 or E-mail your request, including your address to <bm79K@nih.gov>.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: December 17, 1998.

Ben Fulton,

Executive Officer, NICHD.

[FR Doc. 98–34528 Filed 12–29–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Susan S. Rucker, J.D., Patent and licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone 301/496–7057 ext. 245; fax: 301/402–0220; e-mail: sr156v@nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

cDNA Encoding A Gene, BOG (B5T Over-Expressed Gene), And Its Protein Product

SS Thorgeirsson, JT Woitach, M Zhang (NCI) Serial Nos. 60/079,567 filed 27 Mar 98 and 60/075,922 filed 25 Feb 98.

These applications describe a newly identified gene, termed BOG (B5t Over-Expressed Gene), and its protein product. Rat, murine and human homologs of the gene are described. Human BOG has been mapped to chromosome 20 and murine BOG to chromosome 2.

The applications describe the binding of the BOG gene product with the gene product pRb, of the well-known tumor suppressor gene RB (retinoblastoma susceptibility gene). The complex formed between Rb and BOG typically does not contain E2F–1 *in vivo.* This binding property suggests that cells which are transformed/transfected with cDNA or other functional nucleotide sequences which encode the BOG gene product will be useful as tools for studying cell cycle control and oncogenesis.

Studies using rat liver epithelial cell (RLE) lines which are resistant to the growth inhibitory effects of TGF-β1 and primary liver tumors have been shown to over-express BOG. In addition, when normal RLE continuously over-express BOG the cells become transformed and the transformed cells are able to form hepatolblastoma-like tumors when transplanted into nude mice. BOG antisense nucleotides can be used to restore sensitivity to TGF-β in cells which over-express BOG. Therefore, biologics derived from BOG may be useful as diagnostics or therapeutics.

Thymosin α1 Promotes Tissue Repair, Angiogenesis and Cell Migration

KM Malinda, HD Kleinman (NIDCR), RK Maheshwari, and A Goldstein, Serial Nos. 09/186,476 filed 04 Nov 98, 60/069,590 filed 12 Dec 97, and 60/065,032 filed 10 Nov 97.

These applications describe the use of the compound thymosin α1 as an agent for promoting wound healing. Thymosin α1 is a small, 28 mer, peptide which can be made by chemical synthesis or recombinantly. Studies using a punch model for wounds in rats have shown that providing thymosin α1 either intraperitoneally or topically accelerates wound healing. In addition, thmosin α1 has been shown to promote endothelial and keratinoctye cell migration *in vivo* and to promote angiogenesis *in vivo.*

This work has been published in *J. Immunol.* 160(2); 1001–6 (Jan 15, 1998).

Double-Stranded RNA Dependent Protein Kinase Derived Peptides To Promote Proliferation of Cells and Tissues in a Controlled Manner

DP Bottaro (NCI), R Petryshyn (EM), Serial No. PCT/US97/14350 filed 29 Jul 97 and 60/023,307 filed 30 Jul 97

These applications describe a number of peptides having a minimum size of eight (8) amino acids which act as

antagonists of PKR (Protein Kinase R). PKR is a critical enzyme in the interferon signaling pathway which has been implicated in cross-talk between the interferon signaling pathway and the TNF-α apoptosis signaling pathway. The peptide antagonists described herein may be use to inhibit apoptosis or to stimulate cell proliferation under conditions of cell cycle arrest, reduced growth or quiescence leading to possible applications in wound healing, cell culture, or skin grafts.

A portion of this work has appeared in Virology 222 (1): 193–200 (August 1, 1996).

AAV4 Vector and Uses Thereof

JA Chiorini, RM Kotin, B Safer (NHLBI), Serial No. 60/025,934 filed 09 Sept 96 and PCT/US97/16266

These patent applications describe the cloning and characterization of the full-length genome of adeno-associated virus type 4 (AAV4). AAV4, like other members of the AAV family may be useful as a vector for gene therapy.

When compared to AAV2 AAV4 may be better suited as a vector due to its larger size which permits efficient encapsidation of a larger recombinant genome, its greater buoyant density which allows for easier separation of AAV4 from contaminating helper virus. Other characteristics of AAV4 which distinguish it from AAV2 and AAV3 are its expanded promoter region, its distinct capsid protein, its different tissue tropism and its ability to bind hemagluttinin (HA). While AAV4 has several distinguishing characteristics from AAV2 and AAV3 it also shares significant homology, greater than 90%, with the Rep proteins of AAV2 and AAV3.

Studies using a lacZ reporter gene suggest that AAV4 can transduce human, monkey, and rat cells. Other studies comparing transduction efficiencies in a number of cell lines, competition cotransduction experiments and the effect of trypsin on transduction efficiency suggest that the cellular receptor for AAV4 is distinct from that of AAV2.

This research has been published in J. Virology 71(9): 6823–33 (Sept 1997) and as PCT Publication 98/11244 (March 19, 1998).

Dated: December 21, 1998.

Jack Spiegel, Ph.D.,

Director, Division of Technology Development and Transfer Office of Technology Transfer.

[FR Doc. 98–34529 Filed 12–29–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel Hemophilia and vWD Resource

Date: January 13, 1999

Time: 11:00 AM to 1:00 PM

Agenda: To review and evaluate grant applications

Place: Rockledge Bldg. II, Bethesda, MD 20892, (Telephone Conference Call)

Contact Person: David T. George, PHD, MD, Scientific Review Administrator, NIH, NHLBI, DEA, Review Branch, Rockledge Building II, Room 7188, 6701 Rockledge Drive, MD 20892–7924, 301/435–0288

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel GenHAT

Date: January 25, 1999

Time: 7:00 PM to 9:00 PM

Agenda: To review and evaluate grant applications

Place: Gaithersburg Hilton Hotel, 620 Perry Parkway, Gaithersburg, MD 20877

Contact Person: Anthony M. Coelho, PHD, Leader, Clinical Studies, SRG, NIH, NHLBI, DEA, Rockledge Center II, 6701 Rockledge Drive, Room 7194, Bethesda, MD 20892–7924, (301) 435–0288

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel IRAS Family Study: Genetics of Insulin Resistance

Date: January 25–26, 1999

Time: January 25, 1999, 9:00 PM to 10:00 PM

Agenda: To review and evaluate grant applications

Place: Gaithersburg Hilton Hotel, 620 Perry Parkway, Gaithersburg, MD 20877

Time: January 26, 1999, 8:00 AM to 9:00 AM

Agenda: To review and evaluate grant applications

Place: Gaithersburg Hilton Hotel, 620 Perry Parkway, Gaithersburg, MD 20877

Contact Person: Anthony M. Coelho, PHD, Leader, Clinical Studies SRG, NIH, NHLBI, DEA, Rockledge Center II, 6701 Rockledge Drive, Room 7194, Bethesda, MD 20892–7924, (301) 435–0288

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel MDECODE Cooperative Research Program

Date: January 26, 1999

Time: 9:00 AM to 10:00 AM

Agenda: To review and evaluate grant applications

Place: Gaithersburg Hilton Hotel, 620 Perry Parkway, Gaithersburg, MD 20877

Contact Person: Anthony M. Coelho, PHD, Leader, Clinical Studies, SRG, NIH, NHLBI, DEA, Rockledge Center II, 6701 Rockledge Drive, Room 7194, Bethesda, MD 20892–7924, (301) 435–0288

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: December 23, 1998.

Anna Snouffer,

Acting Committee Management Officer, NIH.

[FR Doc. 98–34533 Filed 12–29–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Advisory Council